Evidence map›Paper›PMID 37640233›Full record

ArticleJournal of theoretical biology2023

Modeling the XBB strain of SARS-CoV-2: Competition between variants and impact of reinfection.

Ziqiang Cheng, Yinglei Lai, Kui Jin, Mengping Zhang, Jin Wang

Open access · greenAbstract read
In one paragraph

Article in Journal of theoretical biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Ziqiang ChengSchool of Mathematics, Hefei University of Technology, Hefei, Anhui 230009, China.
Yinglei LaiSchool of Mathematical Sciences, University of Science and Technology of China, Hefei, Anhui 230026, China.
Kui JinDepartment of Emergency Medicine, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230001, China.
Mengping ZhangSchool of Mathematical Sciences, University of Science and Technology of China, Hefei, Anhui 230026, China. Electronic address: mpzhang@ustc.edu.cn.
Jin WangDepartment of Mathematics, University of Tennessee at Chattanooga, Chattanooga, TN 37403, USA. Electronic address: jin-wang02@utc.edu.
University of Science and Technology of China · CNHefei University of Technology · CNUniversity of Tennessee at Chattanooga · US

Funding

Experimentally Guided Modeling and Simulation for Cholera DynamicsR15GM131315 · NIGMS · UNIVERSITY OF TENNESSEE CHATTANOOGA · PI WANG, JIN · 2019 to 2021
$568k
NIGMS NIH HHS R15 GM131315
6 · The paper itself

Abstract

XBB, an Omicron subvariant of SARS-CoV-2 that began to circulate in late 2022, has been dominant in the US since early 2023. To quantify the impact of XBB on the progression of COVID-19, we propose a new mathematical model which describes the interplay between XBB and other SARS-CoV-2 variants at the population level and which incorporates the effects of reinfection. We apply the model to COVID-19 data in the US that include surveillance data on the cases and variant proportions from the New York City, the State of New York, and the State of Washington. Our fitting and simulation results show that the transmission rate of XBB is significantly higher than that of other variants and the reinfection from XBB may play an important role in shaping the pandemic/epidemic pattern in the US.

Indexed as

COVID-19ReinfectionSARS-CoV-2Computer SimulationHumansModels, BiologicalNew York CityPandemicsCOVID-19Mathematical modelingSARS-CoV-2 variants

Identifiers

PMID37640233
PMCPMC10592017
OpenAlexW4386189914

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.